Skip to main content
. 2021 Apr 19;7:84. doi: 10.1038/s41420-021-00467-3

Fig. 3. CircSNRK exerts its cardioprotective effect by sponging miR-103-3p.

Fig. 3

A Graphical representation showing the predicted sites of miR-103-3p for binding to circSNRK and the corresponding mutation. B Luciferase activity of primary cardiomyocytes transfected with luciferase-circSNRK-WT and luciferase-circSNRK-Mut. **P < 0.01 vs. miR-103-3p-NC. (n = 3). C qRT-PCR analysis of miR-103-3p in vector or circSNRK overexpression plasmid treated primary cardiomyocytes. ***p < 0.001 vs. vector (n = 6). D qRT-PCR analysis of circSNRK and SNRK mRNA in miR-NC or miR-103-3p treated primary cardiomyocytes. ***p < 0.001 vs. vector (n = 6). E Luciferase reporter assay was used to test the luciferase activity of SNRK promoter region (n = 3). F Luciferase activity of primary cardiomyocytes transfected with luciferase-SNRK 3′ UTR-WT and luciferase-SNRK 3′ UTR-Mut. **P < 0.01 vs. miR-103-3p-NC + SNRK-WT, ###P < 0.001 versus miR-103-3P-NC + circSNRK+ SNRK-WT (n = 3). G SNRK protein level after overexpression of circSNRK. ***p < 0.001 vs. vector (n = 6). H SNRK protein level after overexpression of miR-103-3p. ***p < 0.001 vs. miR103-3p-NC (n = 6). I SNRK protein level after downregulation of miR-103-3p. ***p < 0.001 vs. miR-103-3p-NC (n = 6). J SNRK protein level after circSNRK and miR-103-3p interference in cardiomyocytes. *P < 0.05 vs. Vector + miR-NC, ###P < 0.001 vs. circSNRK + miR-NC, &&P < 0.01 vs. circSNRK + miR-103-3p mimics (n = 3).